

Supplementary file

Table S1. Studies evaluating neoadjuvant radiation therapy in locally advanced breast cancer

Author, year	Stage	NART dose	NART volume	NACT	pCR	TNBC pCR
Riet FG et al., 2017 ¹	T2–4 or N2	45 Gy (18 x 2.5 Gy) 45-55 Gy	WB, SCL, axilla IMC	No	10%	26%
Adams S et al., 2010 ²	IIB–IIIC	45 Gy (25 x 1.8 Gy) 14 Gy	WB, axillary, SCL Tumor boost	Weekly paclitaxel	34%	54%
Bourgier C et al., 2012 ³	NACT–refractory inoperable LABC	50 Gy (25 x 2 Gy) 10-20 Gy	WB, axillary, SCL, IMC Tumor boost	FUN/XUN	50%	NS
Roth SL et al., 2010 ⁴	IIA–IIIC	50 Gy (25 x 2 Gy)	WB, SCL, IMC if medial primaries	EC, AC or CMF	29.2% (56% in cN+)	NS

AC — adriamycin and cyclophosphamide regimen, CMF — cyclophosphamide, methotrexate and 5-fluorouracil (5-FU) regimen; cN+ — patients with clinically positive nodes; EC — epirubicin and cyclophosphamide regimen, FUN/XUN — 5-FU/capecitabine (Xeloda) and vinorelbine (Navelbine) regimen; LABC — locally advanced breast cancer; IMC — internal mammary chain lymph nodes, NART — neoadjuvant radiotherapy; pCR — pathologic complete response; NS — not specified; SCL — supraclavicular lymph nodes; TNBC — triple-negative breast cancer; WB — whole breast

References

1. Riet FG, Fayard F, Arriagada R, et al. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. *Eur J Cancer*. 2017; 76: 45–51, doi: [10.1016/j.ejca.2017.01.022](https://doi.org/10.1016/j.ejca.2017.01.022), indexed in Pubmed: [28267657](https://pubmed.ncbi.nlm.nih.gov/28267657/).
2. Adams S, Chakravarthy AB, Donach M, et al. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. *Breast Cancer Res Treat*. 2010; 124(3): 723–732, doi: [10.1007/s10549-010-1181-8](https://doi.org/10.1007/s10549-010-1181-8), indexed in Pubmed: [20878462](https://pubmed.ncbi.nlm.nih.gov/20878462/).
3. Bourgier C, Ghorbel I, Heymann S, et al. Effect of preoperative rescue concomitant FUN/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer. *Radiother Oncol*. 2012; 103(2): 151–154, doi: [10.1016/j.radonc.2012.01.008](https://doi.org/10.1016/j.radonc.2012.01.008), indexed in Pubmed: [22402230](https://pubmed.ncbi.nlm.nih.gov/22402230/).
4. Roth SL, Audretsch W, Bojar H, et al. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy. *Strahlenther Onkol*. 2010; 186(6): 299–306, doi: [10.1007/s00066-010-2143-0](https://doi.org/10.1007/s00066-010-2143-0), indexed in Pubmed: [20495968](https://pubmed.ncbi.nlm.nih.gov/20495968/).